Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 25;15(23):5575.
doi: 10.3390/cancers15235575.

Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors

Claire K Mulvey  1
Affiliations
Review

Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors

Claire K Mulvey. Cancers (Basel). .

Abstract

Well-differentiated lung neuroendocrine tumors (LNETs) are heterogeneous cancers that are increasing in incidence. Treatment options for LNETs have expanded in recent years, and our knowledge of the molecular subtypes has also advanced. Multidisciplinary teams have an established role in personalizing the best treatment for individual patients. Other precision medicine approaches for the treatment of LNETs have lagged behind those for non-small-cell lung cancer, with only rare actionable molecular alterations identified and few established predictive factors to guide therapy selection. However, as summarized in this review, there is increasing potential for personalized treatment of patients with LNETs. In particular, advances in radiotheragnostics may allow us to tailor the treatment of individual patients with NETs in the coming years. These advances may soon deliver the promise of more effective, less toxic treatments and better outcomes for patients with these increasingly common cancers.

Keywords: carcinoid tumors; lung neuroendocrine tumors; precision medicine; theragnostics.

PubMed Disclaimer

Conflict of interest statement

C.M. has served as an advisor to Jazz Pharmaceuticals and received research funding from her institution as a local clinical trial principal investigator for RayzeBio.

Figures

Figure 1
Figure 1
New frontiers in peptide receptor radionuclide therapy. SSA = somatostatin analog; SSTR = somatostatin receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Travis W.D., Brambilla E., Nicholson A.G., Yatabe Y., Austin J.H.M., Beasley M.B., Chirieac L.R., Dacic S., Duhig E., Flieder D.B., et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 2015;10:1243–1260. doi: 10.1097/jto.0000000000000630. - DOI - PubMed
    1. Rekhtman N. Lung neuroendocrine neoplasms: Recent progress and persistent challenges. Mod. Pathol. 2022;35:36–50. doi: 10.1038/s41379-021-00943-2. - DOI - PMC - PubMed
    1. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. doi: 10.1002/cncr.11105. - DOI - PubMed
    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
    1. Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204–2210. doi: 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R. - DOI - PubMed

LinkOut - more resources